Dysplastic nevus syndrome (DNS) by Viguié, C






Cancer Prone Disease Section 
Mini Review 
 
Atlas Genet Cytogenet Oncol Haematol. 1999; 3(4)  
 
212 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
OPEN ACCESS JOURNAL AT INIST-CNRS 
Dysplastic nevus syndrome (DNS) 
Claude Viguié 
Service de Dermatologie, Hôpital Tarnier-Cochin, 89 rue d'Assas, 75006 Paris, France (CV) 
 
Published in Atlas Database: October 1999 
Online updated version : http://AtlasGeneticsOncology.org/Kprones/DysplNevusID10013.html 
DOI: 10.4267/2042/37570 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 1999 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
 
Identity 
Alias: Familial atypical mole-malignant melanoma 
syndrome (FAMMM); B-K mole syndrome 
Inheritance: Autosomal dominant with high 
penetrance and variable expressivity; the frequency  
 
of DNS is difficult to evaluate because a number of  
cases without malignant evolution are not recorded; 
DNS defines patients with numerous dysplastic nevi. 
FAMMM defines families where coexist numerous 
nevi with malignant melanoma (MM).Sporadic forms 
of dysplastic nevi are not considered as DNS. 
 
 
Multiple dysplastic naevi on the skin of the back, with (left) a surgically resected malignant melanoma on the scalp - Courtesy Daniel 
Wallach. 
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The familial dysplastic nevus syndrome is a good 
example of a genetic disorder which leads to the 
practice of self prevention and prevention at the family 
level; the risk is the evolution towards MM. 
Phenotype and clinics 
Predominant in patients with a clear complexion, blue 
eyes and/or presence of numerous nevi; the dysplastic 
nevus or "nevus of Clark" or "atypical melanocytic 
nevus" is a large mole with a variable size (5 to 15 
mm), an irregular border and a color varying from dark 
brown to depigmentation; lesions are located mainly o  
the upper trunk, back, limbs, abdomen and arms; the 
number of moles is variable, from 10 to up to 100. 
Histologic studies show the dysplastic nature of these 
nevi: junctional hyperplasia with isolated or clustered 
melanocytes, cells with large, irregular, 
hyperchromatic, and non mitotic nucleus; this aspect is 
intermediate between benign nevus and MM. 
Neoplastic risk 
The main risk is to develop a MM but there is also a 
possible increased incidence of pancreatic cancer, 
breast cancer, and myeloma; MM usually arises from a 
dysplastic nevus (DN) but it can also appear de novo or 
from a benign nevus; it occurs most often in the skin 
but it may also involve other sites, mainly the eye or 
the central nervous system; the risk of MM depends on 
three factors:  
1- The number of nevi: MM occurs in 2 to 7% of the 
population; without DN the risk is multiplied by 2 if the 
total number of nevi is higher than 25; the risk is 
multiplied by 4 if they are more than 5 nevi with a 
diameter higher than 5 cm; the risk is multiplied by 2 
with one DN and by 12 with 10 DN; 40% of MM occur 
on dysplastic nevi, more frequently in superficial than 
nodular forms. 
2- The existence of at least one case of MM in the 
family (risk x 2); the risk of MM is 100% in case of
FAMMM; the patients with DNS who develop MM are 
notably younger than patients with sporadic forms; the 
age of onset in FAMMM regresses from generation to 
generation. 
3- The role of UV as a promoting factor is discussed; 
the number of DN increases with sun exposure. 
Treatment 
Clinical vigilance and tumour exeresis. 
Evolution 
The number of DN can increase during life with an 
increase in MM risk. 
Prognosis 






A chromosome instability disorder was observed in cell 
cultures from the normal skin and dysplastic nevi over 
three-generations in DNS families, leading to 
translocations, duplications and deletions; in another 
study on MM, translocations involving bands 11q24, 
1q25 and Xq13 were observed in patients with DNS, in 
dysplastic nevi and in the normal skin as well; a loss of 
chromosome 9 was found in 2 out of 4 DN, suggesting 
that deletion / inactivation of a gene on 9p may be a 
primary event in melanocyte transformation; loss of 
heterozygocity (LOH) for markers flanking the 
CDKN2A on 9p was described in primary MM and in a 
metastasis; other putative tumor suppressor genes 
which could be involved in the process are located in 
1p13, 10p, 10q, 11q and 6q15-q23. 
DNS is characterized cytogeneticaly by an UV-induced 
elevated level of sister chromatid exchange (SCE); the 
post-UV plasmid hypermutability test is a laboratory 
marker for FAMMM patients, suggesting a defective 
repair mechanism of UV-induced DNA damage; 
deficient DNA repair in lymphocyte studies also 
characterizes some patients with sporadic dysplastic 
nevi or non familial MM. 
Genes involved and proteins 
Still unknown 
Location 
Locus in 1p36 (called CMM1 for cutaneous malignant 
melanoma): this locus segregates with MM and DNS, 
but no gene is yet cloned. 
CDKN2C/p18 (cyclin-dependent kinase 
inhibitor 2) 
Location 
Locus in 1p32; this locus has been found mutated in the 
germline from patients with MM and other tumors. 
CDKN2A/p16/MTS1/CDK4 inhibitor 
(cyclin-dependent kinase inhibitor 2A) 
Location 
Locus in 9p21; this locus has been designated as 
CMM2; germline mutations were found in this locus in 
30 to 40% of patients with FAMMM, and in some 
patients with two cutaneous and/or mucous MM; P16 is 
a candidate gene for MM susceptibility; there is a p16 
mutation in 10 to 14% of patients suffering from 
sporadic multifocal MM; P16 is also involved in 
several other types of cancers; other tumor suppresso  
genes located at 9p are hypothetically involved in MM
progression. 
CDK4 (cyclin dependent kinase) 
Location 
Locus in 12q14; 2 germline mutations found in 3 
FAMMM families. 
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Locus in 6q: a 6q allelic loss was identified in 21 of 53 
informative loci; the chromosomal region bearing the 
highest frequency of 6q allelic loss was defined by the 
markers MYB and ESR located at 6q22-q23 and 6q24-
q27, respectively; this may indicate genetic 
heterogeneity. 
MC1R (melanocortin receptor) 
Location 




17p13; P53 mutations were found in benign and 
dysplastic nevi from patients with previous personal or 
familial history of MM; however, these mutations are 
considered to be late events and cannot be used as a 
marker to identify patients at high risk of MM. 
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